Short Interest in Sensei Biotherapeutics, Inc. (NASDAQ:SNSE) Decreases By 33.7%

Sensei Biotherapeutics, Inc. (NASDAQ:SNSE) was the target of a large decrease in short interest in the month of December. As of December 31st, there was short interest totaling 25,945 shares, a decrease of 33.7% from the December 15th total of 39,109 shares. Approximately 2.7% of the company’s shares are short sold. Based on an average trading volume of 34,460 shares, the short-interest ratio is currently 0.8 days. Based on an average trading volume of 34,460 shares, the short-interest ratio is currently 0.8 days. Approximately 2.7% of the company’s shares are short sold.

Wall Street Analyst Weigh In

Several equities analysts have recently weighed in on the company. Wall Street Zen raised Sensei Biotherapeutics to a “hold” rating in a research note on Saturday, December 27th. Weiss Ratings reiterated a “sell (d-)” rating on shares of Sensei Biotherapeutics in a research note on Monday, December 29th. Finally, HC Wainwright downgraded shares of Sensei Biotherapeutics from a “buy” rating to a “neutral” rating in a research note on Thursday, October 30th. One equities research analyst has rated the stock with a Strong Buy rating, one has given a Buy rating, one has assigned a Hold rating and one has assigned a Sell rating to the stock. According to MarketBeat, Sensei Biotherapeutics currently has a consensus rating of “Moderate Buy” and an average target price of $55.00.

Sensei Biotherapeutics Stock Performance

Shares of SNSE stock traded down $1.17 on Friday, hitting $10.44. The stock had a trading volume of 74,872 shares, compared to its average volume of 75,564. The stock’s 50 day moving average is $9.41 and its 200-day moving average is $9.14. The firm has a market capitalization of $13.15 million, a price-to-earnings ratio of -0.55 and a beta of 0.28. Sensei Biotherapeutics has a 52-week low of $5.00 and a 52-week high of $18.35.

Sensei Biotherapeutics (NASDAQ:SNSE) last issued its quarterly earnings data on Friday, November 14th. The company reported ($3.62) EPS for the quarter, topping analysts’ consensus estimates of ($4.11) by $0.49. Equities analysts expect that Sensei Biotherapeutics will post -1.17 earnings per share for the current year.

Insider Transactions at Sensei Biotherapeutics

In other news, major shareholder James Peyer sold 3,507 shares of the business’s stock in a transaction on Tuesday, December 9th. The shares were sold at an average price of $7.96, for a total transaction of $27,915.72. Following the completion of the sale, the insider directly owned 155,142 shares of the company’s stock, valued at $1,234,930.32. The trade was a 2.21% decrease in their position. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available at this link. Insiders have sold 27,907 shares of company stock valued at $287,280 in the last ninety days. 23.20% of the stock is currently owned by insiders.

Sensei Biotherapeutics Company Profile

Sensei Biotherapeutics, Inc is a clinical-stage biotechnology company focused on the discovery and development of immunotherapies that harness both the innate and adaptive arms of the immune system to treat cancer and autoimmune diseases. Utilizing proprietary antibody engineering and biologics platforms, Sensei aims to develop next-generation checkpoint modulators and immune agonists designed to overcome the limitations of current therapies.

The company’s lead programs include SIS-100, a first-in-class antagonist targeting Siglec-15 being evaluated in solid tumors to relieve immune suppression in the tumor microenvironment, and SIS-101, an antibody directed against CD39 intended to restore T-cell function by modulating adenosine signaling pathways.